Large Outflow of Money Witnessed in Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. (REGN) surged 0.98% during the last session. The last traded price was up 3.51 points at $362.8. The data for the fund flow suggests that the net intraday money flow was $(-3.54) million. The fund value in upticks was recorded to be $81.83 million and in downticks, it was found to be $85.38 million. The up/down ratio for the day was measured to be 0.96. For the week, the shares have seen a percentage change of 4.7%.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of Regeneron Pharmaceuticals, Inc. appreciated by 4.37% during the last five trading days but lost 0.8% on a 4-week basis. Regeneron Pharmaceuticals, Inc. is up 5.55% in the last 3-month period. Year-to-Date the stock performance stands at -0.8%. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rose 1.36% or 4.88 points on Wednesday and made its way into the gainers of the day. After trading began at $358.74 the stock was seen hitting $364.8 as a peak level and $355.01 as the lowest level. The stock ended up at $364.17. The daily volume was measured at 1,033,030 shares. The 52-week high of the share price is $452.96 and the 52-week low is $325.35. The company has a market cap of $38,409 million.

Company has reported several Insider transactions to the SEC, on Dec 14, 2016, Charles A Baker (director) sold 3,000 shares at 392.48 per share price.On Nov 16, 2016, Arthur F Ryan (director) sold 2,000 shares at 429.34 per share price.On Nov 15, 2016, Joseph L Goldstein (director) sold 2,125 shares at 450.00 per share price.

Regeneron Pharmaceuticals Inc Last issued its quarterly earnings results on Nov 4, 2016. The company reported $3.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.43. Analyst had a consensus of $2.70. The company had revenue of $1220.00 million for the quarter, compared to analysts expectations of $1276.06 million. The companys revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.90 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Regeneron Pharmaceuticals Inc was Reiterated by RBC Capital Mkts on Jan 6, 2017 to Outperform, Lowers Price Target to $ 598 from a previous price target of $626 .Regeneron Pharmaceuticals Inc was Reiterated by Chardan Capital Markets on Jan 6, 2017 to Neutral, Lowers Price Target to $ 345 from a previous price target of $350 .Regeneron Pharmaceuticals Inc was Upgraded by Credit Suisse to Outperform on Dec 20, 2016. Company shares were Upgraded by Chardan Capital Markets on Dec 12, 2016 to Neutral, Raises Price Target to $ 350 from a previous price target of $300 .Regeneron Pharmaceuticals Inc was Reiterated by Chardan Capital Markets on Nov 7, 2016 to Sell, Lowers Price Target to $ 300 from a previous price target of $325 .

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regenerons platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)


Share this post

Leave a Reply